ESTRO Vision 2030.
"Radiation Oncology. Optimal Health for all, together."
If, by 2035, every cancer patient who needs radiotherapy has access to it, almost one million more lives will be saved every year worldwide.
Become an ESTRO member
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial - Read It Corner
PROSPECT trial adds another treatment possibility for patients with resectable rectal cancer
Course Report Multidisciplinary Management of Breast Cancer 2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer - Read It Corner
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial - Read It Corner